T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 22, 2023
17 Maio 2023 - 5:05PM
T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid
detection of sepsis-causing pathogens and antibiotic resistance
genes, announced today that it has rescheduled its first quarter
2023 financial results reporting to before market open on
Monday, May 22, 2023. Company management will host a
corresponding conference call beginning at 8:30 a.m. Eastern
Time.
Investors interested in listening to the
conference call may do so by accessing a live and archived webcast
of the event at www.t2biosystems.com, on the Investors page in
the Events & Presentations section. To listen to the conference
call, please dial 1-877-545-0523 (US/Canada) or 1-973-528-0016
(International), passcode 717782, approximately ten to five minutes
prior to the start time.
About T2 Biosystems:T2
Biosystems, a leader in the rapid detection of sepsis-causing
pathogens and antibiotic resistance genes, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, the T2Bacteria®
Panel, the T2Candida® Panel, the T2Resistance® Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Biothreat™ Panel, the T2Cauris™
Panel, and T2Lyme™ Panel, as well as next-generation products for
the detection of bacterial and fungal pathogens and associated
antimicrobial resistance markers. For more information, please
visit www.t2biosystems.com.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupir@T2Biosystems.com415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024